Safety, Tolerability, and Pharmacokinetics of Two Dose Strengths of a Single Subcutaneous Dose of BI 655130 and One Single Intravenous Dose of BI 655130 in Healthy Male and Female Subjects (Open-label, Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Spesolimab (Primary) ; Spesolimab (Primary)
- Indications Pustular psoriasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 29 Dec 2017 to 10 Jan 2018.
- 09 Jan 2018 Planned primary completion date changed from 29 Dec 2017 to 10 Jan 2018.